



Where's the weak link in your operations?

Biotech companies produce vast amounts of data, lab books & documents, cultures, compounds, samples, prototypes, plans and other valuable R&D materials that would, if damaged or destroyed, prove costly to replace or recreate.

A fire, flood, freezer breakdown or other unwelcome event will keep you busy replacing lost materials or repeating critical R&D projects. While you're struggling to find the extra cash to pay for that, you'll also need to continue to fund your regular monthly overheads – fixed costs such as staff salaries and rent payments.

- Would your cash flow hold up under the strain?
- What if the extra work caused you to miss a milestone payment, or postpone a product launch?
- If you outsource your R&D work to others, who pays to replace it if things go wrong?


Biotech firms engaged in R&D need specialist advice and insurance to help meet such costs. Your investors will expect nothing less. Without it, you're jeopardising cash flow at your most vulnerable phase - pre-clinical R&D.

Want to know more? Let's talk.

matthew.clark@laplaya.co.uk Tel. 01223 200667

www.laplaya.co.uk

La Playa Science & Technology: Insurance with Intelligence



LA PLAYA LIMITED